ArticleBioinformation2024
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The second most common malignant tumour in women worldwide, cervical cancer seriously jeopardizes their health. It has been established that a high-risk Human papillomavirus (HPV) infection is the cause of cervical cancer. Cervical cancer is associated with several risk factors, including reproductive, behavioural and sexual characteristics. Many Siddha practitioners often prescribe Thanga uram (TU), a Siddha metallo-mineral formulation, for genito-urinary diseases, infertility, varicose veins and leucorrhoea. This study aims to evaluate the anti-cancer activity of "Thanga uram" against HeLa cell lines. Hela cell lines were used to assess the antiproliferative activity TU using the MTT assay and apoptosis by Annexin V flow cytometry. Thanga uram produced dose-dependent cytotoxic effects against HeLa cell lines with an LC50 value of 145.891µg/mL. Further investigation, using Annexin V flow cytometry, equivalently revealed the late apoptotic effect, with a percentage value of 28.15. Thus, the current study evaluates the effectiveness of Thanga Uram against cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.